Celgene to defend Revlimid patents after challenge by Natco Pharma

Celgene announced that Indian drugmaker Natco Pharma filed a regulatory application with the FDA seeking approval to market a generic version of Revlimid (lenalidomide).

The drug, which generated $587 million in revenue during the second quarter of the year, is protected by 12 patents and has further patent applications pending, according to Celgene. The company said it "intends to vigorously enforce its…intellectual property rights for Revlimid and plans to file a complaint alleging infringement" by Natco.

Last month, Celgene indicated it expected a patent challenge over Revlimid after the FDA announced that a patent certification for the drug was submitted by an undisclosed party on July 12.

To read more Top Story articles, click here.